Who is sponsoring NCT05466565?

NCT05466565 is sponsored by Xiangya Hospital of Central South University.

What condition does NCT05466565 study?

NCT05466565 studies Hepatocellular Carcinoma.

What is the status of NCT05466565?

NCT05466565 is currently RECRUITING.

Last reviewed 2022-07-20 · How we verify

Antiviral Therapy for Patients With Liver Cancer After Surgery

NCT05466565 RECRUITING

This is a single-center, prospective, observational, real world study designed to evaluate the effects of peginterferon α-2b(pegabin) combined with nucleoside (acid) analogs (entecavir,ETV tenofovir,TDF tenofovir alafenamide,TAF) on patients after radical surgery for hepatitis B associated hepatocellular carcinoma by collecting data from patients at our hospital

Details

Lead sponsor	Xiangya Hospital of Central South University
Status	RECRUITING
Enrolment	360
Start date	Wed Dec 01 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Fri Dec 31 2027 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

Hepatocellular Carcinoma

Countries

China